June 16, 2020

expert reaction to the MHRA suspending recruitment to hydroxychloroquine trials for COVID-19

The Medicines and Healthcare products Regulatory Agency (MHRA) have announced the suspension of recruitment to hydroxychloroquine trials for COVID-19.

Dr Stephen Griffin, Associate Professor in the School of Medicine, University of Leeds, said:

“Hydroxychloroquine has been conclusively shown not to confer clinical benefit to SARS-COV-2 infected patients by the RECOVERY trial.  It therefore makes sense for the MHRA to suspend further recruitment to trials in order that patients don’t take this medicine unnecessarily.  The FDA similarly revoked emergency approval for the drug in COVID19 patients.  This demonstrates the value of controlled trials during the ongoing crisis.”

https://www.gov.uk/government/news/mhra-suspends-recruitment-to-covid-19-hydroxychloroquine-trials

All our previous output on this subject can be seen at this weblink:

www.sciencemediacentre.org/tag/covid-19

Declared interests

Dr Stephen Griffin: “No conflicts.”